Coronary/Structural Heart

Cardiac Dimensions Announces DRG Reimbursement Code for Carillon Mitral Contour System in Germany

KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced that InEK, the German Institute for the Hospital Remuneration System, has granted a permanent DRG (Diagnosis Related Group) code covering reimbursement for the company’s Carillon® Mitral Contour […]

New Study Shows Abbott’s Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care

ABBOTT PARK, Ill., Oct. 17, 2018 /PRNewswire/ — For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient’s side in as […]

Neovasc Announces Publication of a Peer-Reviewed Article on Tiara™ Cases in Circulation: Cardiovascular Interventions

VANCOUVER, Oct. 16, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an original article was published in Circulation: Cardiovascular Interventions titled […]

NobleStitch™ EL Again Expands Global Base With New Center In Ireland

BELFAST, Ireland, Oct. 11, 2018 /PRNewswire/ — NMT2 is excited to announce its expansion of NobleStitch™ EL into the Irish market with first series of PFO closure cases in Belfast, Ireland.  Dr. Mark Spence MD, Interventional Cardiologist and co-founder of the Structural Heart Disease Program at Belfast Health and Social Care Trust in Belfast successfully performed the first procedures […]

Micro Interventional Devices, Inc.™ Successfully Treats First-in-Human Patient with Percutaneous MIA™, Minimally Invasive Annuloplasty Technology

NEWTOWN, Pa., Oct. 12, 2018 /PRNewswire/ — Micro Interventional Devices, Inc.™ (MID) announced today the world’s first percutaneous implantation of its MIA™, Minimally Invasive Annuloplasty, technology for tricuspid and mitral repair.  This marks the first patient enrolled in the transcatheter arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) trial being conducted in Europe. […]

CHF Solutions Initiates Strategic Collaboration with NI Medical on Management of Fluid Overloaded Patients

EDEN PRAIRIE, Minn., Oct. 11, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today that it has entered into a collaboration agreement with NI Medical to explore potential clinical synergies between the company’s Aquadex FlexFlow® System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume status and […]

Transseptal Solutions Announces FDA Clearance of Its Novel Transseptal Access System for Transseptal Puncture and Left Atrial Navigation

NETANYA, Israel, October 11, 2018 /PRNewswire/ — Transseptal Solutions Ltd., developer of an innovative Transseptal Access System with a novel approach of transseptal puncture and left atrial navigation to introduce various cardiovascular catheters into the left heart chambers, announced today that the company has received FDA 510(k) clearance for the TSP Crosser[TM] Transseptal Access System. […]

Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

VANCOUVER, Oct. 10, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the “FDA”) […]

Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

WARREN, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), as […]

Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve

IRVINE, Calif., Oct. 8, 2018 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has commenced the U.S. pivotal trial that will study its self-expanding CENTERA transcatheter valve for severe, symptomatic aortic stenosis (AS) patients at intermediate […]